Orchard Therapeutics Plc Revenue Growth Rates (ORTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Orchard Therapeutics Plc  (NASDAQ: ORTX)
 

ORTX's Revenue Growth by Quarter and Year

Orchard Therapeutics Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORTX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 6.30
2nd Quarter June 7.31
1st Quarter March 1.24
FY 14.85

ORTXs Annual Revenue
Orchard Therapeutics Plc's Revenue in the fiscal year 2022 $ 22.66 millions
Orchard Therapeutics Plc's Revenue in the fiscal year 2021 $ 1.68 millions
Orchard Therapeutics Plc's Revenue in the fiscal year 2020 $ 2.60 millions
Orchard Therapeutics Plc's Revenue in the fiscal year 2019 $ 2.51 millions
Orchard Therapeutics Plc's Revenue in the fiscal year 2018 $ 2.08 millions




ORTX Revenue third quarter 2023 Y/Y Growth Comment
Orchard Therapeutics Plc reported Revenue growth of 9.03% year on year in the third quarter 2023, to $ 6.30 millions, this is lower than Orchard Therapeutics Plc's recent average Revenue surge of 9.8874482728181E+15%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Revenue growth. While Orchard Therapeutics Plc' s Revenue increase of 9.03% ranks overall at the positon no. 1323 in the third quarter 2023.


ORTX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 1356.25 % - -
3rd Quarter September 9.03 % 385.71 % -40.5 % 4.17 %
2nd Quarter June 67.28 % - - -
1st Quarter March -77.54 % - - -
FY   - 1256.89 % -35.77 % -

Financial Statements
Orchard Therapeutics Plc's third quarter 2023 Revenue $ 6.30 millions ORTX's Income Statement
Orchard Therapeutics Plc's third quarter 2022 Revenue $ 5.78 millions Quarterly ORTX's Income Statement


ORTX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 20.93 % -59.66 % -
3rd Quarter September -13.79 % 32.27 % - 233.33 %
2nd Quarter June 489.52 % -20.83 % - -
1st Quarter March -82.26 % 1050 % - -
FY (Year on Year)   - 1256.89 % -35.77 % -


Back to ORTX Growth rate Comparisons >> Back to ORTX Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #292
Overall #1323

Revenue Y/Y Growth Statistics
High Average Low
1.0E+17 % 9.8874482728181E+15 % -100 %
  (Jun 30 2021)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #292
Overall #1323
Revenue Y/Y Growth Statistics
High Average Low
1.0E+17 % 9.8874482728181E+15 % -100 %
  (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Orchard Therapeutics Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1043.69 % 84.09 % -100 %
(Mar 31 2022)  


ORTX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Orchard Therapeutics Plc disclosed drop in Revenue from the second quarter by -13.79% to $ 6.30 millions, from $ 7.31 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Orchard Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 3508.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #64
Healthcare Sector #531
Overall #3508
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #64
Healthcare Sector #531
Overall #3508
Revenue Q/Q Growth Statistics
High Average Low
1043.69 % 84.09 % -100 %
(Mar 31 2022)  


ORTX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Orchard Therapeutics Plc disclosed drop in Revenue from the second quarter by -13.79% to $ 6.30 millions, from $ 7.31 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Orchard Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 3508.


Orchard Therapeutics Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 21.84 $ 21.31 $ 18.37 $ 22.66 $ 16.15
Y / Y Revenue Growth (TTM) 35.21 % 84.27 % - - -
Year on Year Revenue Growth Overall Ranking # 202 # 300 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 2.46 % 16.04 % -18.92 % 40.26 % 39.64 %
Seq. Revenue Growth (TTM) Overall Ranking # 476 # 524 # 547 # 629 # 467


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Orchard Therapeutics Plc's cumulative twelve months Revenue were $ 22 millions, company would post below average annual Revenue growth of 39.64% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Orchard Therapeutics Plc's Revenue growth from the 7.31% growth in Jun 30 2023.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 202, from total ranking in previous quarter at 300.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 74
Overall # 202

Revenue TTM Y/Y Growth Statistics
High Average Low
84.27 %
 59.74 %
35.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 144
S&P 500 # 476
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Orchard Therapeutics Plc's cumulative twelve months Revenue were $ 22 millions, company would post below average annual Revenue growth of 35.21% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Orchard Therapeutics Plc's Revenue growth from the 7.31% growth in Jun 30 2023.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 202, from total ranking in previous quarter at 300.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 74
Overall # 202

Revenue TTM Y/Y Growth Statistics
High Average Low
84.27 %
59.74 %
35.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 144
S&P 500 # 476




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ORTX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Resmed Inc 15.80%$ 15.800 millions
Electromedical Technologies Inc 15.76%$ 15.762 millions
Electromed Inc 15.63%$ 15.631 millions
Tscan Therapeutics Inc 15.58%$ 15.581 millions
Nuwellis Inc 15.30%$ 15.303 millions
Biomarin Pharmaceutical Inc15.04%$ 15.036 millions
Radnet Inc 14.83%$ 14.834 millions
Insmed Inc14.83%$ 14.825 millions
Exelixis Inc 14.62%$ 14.617 millions
Regeneron Pharmaceuticals Inc 14.53%$ 14.526 millions
Intercept Pharmaceuticals inc 14.44%$ 14.437 millions
Biocryst Pharmaceuticals Inc 14.39%$ 14.395 millions
Dbv Technologies S a 14.37%$ 14.368 millions
Orthopediatrics Corp14.31%$ 14.315 millions
Warby Parker Inc 14.08%$ 14.085 millions
Paragon 28 inc 13.87%$ 13.874 millions
Stoke Therapeutics Inc 13.87%$ 13.873 millions
Amneal Pharmaceuticals Inc 13.84%$ 13.836 millions
Artivion Inc 13.58%$ 13.577 millions
Atrium Therapeutics Inc 13.54%$ 13.537 millions
Steris Plc13.50%$ 13.499 millions
Aquestive Therapeutics Inc 13.43%$ 13.426 millions
Ati Physical Therapy Inc 13.18%$ 13.179 millions
Livanova Plc13.14%$ 13.142 millions
Myomo Inc 13.12%$ 13.120 millions
American Oncology Network Inc 13.11%$ 13.111 millions
Scynexis Inc 13.10%$ 13.102 millions
Escalon Medical Corp 13.06%$ 13.060 millions
Emergent Biosolutions Inc 12.71%$ 12.708 millions
Schrodinger Inc 12.60%$ 12.599 millions


About Orchard Therapeutics Plc Revenue Growth Rates (ORTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Orchard Therapeutics Plc (CIK 1748907).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-062428
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Orchard Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.